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Abstract Analysis of the fate of the p185HER2 oncoprotein
following activation by heregulin L1 revealed the induction of the
tyrosine-phosphorylation, down-modulation, and polyubiquitina-
tion of p185HER2. Receptor ubiquitination was suppressed in
cells treated with heregulin L1 in the presence of sodium azide, an
inhibitor of ATP-dependent reactions, or genistein, a tyrosine
kinase protein inhibitor, indicating the requirement for kinase
activity and ATP in p185HER2 polyubiquitination. Ubiquitinated
p185HER2 was degradated by the 26S proteasome proteolytic
pathway. Kinetics and inhibition experiments indicated that
endocytosis of the receptor occurs downstream of the initiation of
the degradation process.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
The c-erbB-2 protooncogene encodes a 185-kDa transmem-
brane glycoprotein (p185HER2) with intrinsic tyrosine kinase
activity belonging to the epidermal growth factor receptor
(EGFR) family [1]. This receptor, whose speci¢c ligand has
not yet been identi¢ed, can be activated by epidermal growth
factor (EGF) through the formation of heterodimers between
HER1 and HER2 [2], or by heregulin through heterodimeri-
zation with HER3 or HER4 [3,4]. The ¢rst event which occurs
rapidly following heregulin treatment is the tyrosine phos-
phorylation of p185HER2 [5], but nothing is known about the
processes that are responsible for degradation of this onco-
protein following its activation.
The ubiquitination pathway has recently been established as
an important mechanism of degradation of cytoplasmic, nu-
clear, and even cell membrane proteins [6]. The presence of
polyubiquitin chains accelerates the rate of protein degrada-
tion by a complex multicatalytic proteinase called 26S protea-
some [7]. This proteasome breaks down the ubiquitinated pro-
tein to short peptides but recycles the ubiquitin molecules.
Monomeric receptors belonging to di¡erent receptor tyrosine
kinase (RTK) families such as the platelet-derived growth
factor receptor [8,9], EGFR, colony-stimulating factor recep-
tor, ¢broblast growth factor receptor are polyubiquitinated
after ligand stimulation [10], supporting the hypothesis that
ubiquitination of the receptor is a general phenomenon for
RTK degradation. For all these molecules, the binding of
the speci¢c ligand rapidly induces the clustering of ligand-
receptor complexes, internalization and ultimately degrada-
tion of both ligand and receptor [11]. Using a chimeric recep-
tor composed of the extracellular EGFR binding domain and
the cytoplasmic domain of the HER2 molecule, it has been
shown that EGFR/HER2 receptors internalize EGF much
more slowly than EGFR [12,13]. A more recent study [14]
showed that the wild-type HER2 receptor failed to associate
with AP2, a clathrin-associated protein complex which inter-
acting with the carboxyl terminus of membrane receptors,
facilitates receptor internalization through coated pits.
In the present study, we showed that heregulin L1 treatment
induced tyrosine phosphorylation, immediately followed by
polyubiquitination and degradation of p185HER2 through
26S proteasome proteolytic pathway and that down-modula-
tion of the membrane receptor after heregulin L1 treatment
required initiation of p185HER2 proteolytic degradation.
2. Materials and methods
2.1. Cell culture
MDAMB453 human breast carcinoma cells were obtained from
American Type Culture Collection (Rockville, MD) and maintained
in RPMI medium (Sigma, St. Louis, MO) supplemented with 10%
fetal calf serum, 2 mM L-glutamine, 0.4 mg/ml gentamycin.
2.2. Reagents
Human puri¢ed recombinant heregulin L1 protein (NeoMarkers,
Freemont, CA) was used at 10 ng/ml. Herbimycin A (HA) (Calbio-
chem, La Jolla, CA), the peptidyl aldehyde inhibitor of the 26S pro-
teasome complex N-acetyl-Leu-Leu-norleucinal (LLnL) (kindly pro-
vided by Dr. G. Draetta) and Genistein (Sigma, St. Louis, MO),
all-dissolved in methylsulfoxide (Me2SO) were used at 3 WM, 50 WM
and 40 Wg/ml, respectively.
Mouse monoclonal antibody (MAb) Ab3, directed against the pep-
tide sequence of the carboxyl domain of the human HER2 gene prod-
uct (Oncogene Science Inc., Manhasset, NY), was used for immuno-
blotting. Mouse MAb MGR2, directed against the extracellular
domain of the p185HER2 [15], was used for immunoprecipitation and
£uorimetric analysis. Mouse anti-phosphotyrosine MAb, directed
against phosphotyramine-KLH, was purchased from Upstate Biotech-
nology Inc. (Lake Placid, NY). Anti-ubiquitin serum, derived from
rabbits immunized with bovine red blood cell ubiquitin conjugated to
KLH, was purchased from Sigma (St. Louis, MO).
2.3. Immunoprecipitation and immunoblotting
MDAMB453 cells in log phase in 6-well plates were starved for 24
h and treated or not for 6 h with HA, overnight with LLnL, 1 h with
genistein or 15 min with 0.2% sodium azide. Cells were then stimu-
lated with heregulin L1 (10 ng/ml) at di¡erent times and lysed by
scraping into lysis bu¡er consisting of 1% NP40, 0.1% SDS, 50 mM
Tris-HCl, pH 7.5, 1 mM PMSF, 10 Wg/ml leupeptin, 10 Wg/ml apro-
tinin, 1 mM pepstatin, 1 mM NaVO4, 5 mM. Lysates were immuno-
precipitated as described [16] with MAb MGR2. Immunoprecipitates
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were subjected to immunoblot analysis with MAb Ab3 or anti-phos-
photyrosine (1.5 Wg/ml) or with anti-ubiquitin antiserum (1 Wg/ml) and
the proteins were visualized using the ECL Western blotting detection
system (Amersham, Little Chalfont, UK).
2.4. Flow cytometric analysis
Indirect immuno£uorescence assays on cells treated with heregulin
L1 (10 ng/ml) for various periods of time at 37‡C with or without
biochemical inhibitors, were performed using MAb MGR2 (10 Wg/ml)
and £uorescein isothiocyanate (FITC)-conjugated sheep-anti-mouse
IgG secondary antibody (Keerkegaard p Perry Laboratories Inc.,
Gaithersburg, MD). Fluorescence was evaluated by FACScan (Becton
Dickinson, Mountain View, CA) using Lysis II software.
3. Results and discussion
3.1. Heregulin L1 causes phosphorylation, down-modulation
and ubiquitination of p185HER2 receptor
When MDAMB453 cells were stimulated with heregulin L1,
the tyrosine phosphorylation of the immunoprecipitated
p185HER2 oncoprotein reached a peak within 1 min of stim-
ulation and returned to basal levels after 15 min of treatment
(Fig. 1A, compare lanes 2 and 4). The receptor was also
down-modulated: after 60 min of treatment, the quantity of
oncoprotein was reduced by half (Fig. 1B, lane 6). The
p185HER2 immunoprecipitates were also stained with anti-
ubiquitin antibodies. Polyubiquitinated p185HER2, resolving
as smeared high molecular weight bands, was detectable with-
in 5 min of heregulin L1 treatment and decreased by 10 min
after stimulation (Fig. 1C). The kinetics of tyrosine phospho-
rylation, down-modulation and ubiquitination suggests that
the ¢rst event is phosphorylation, followed by ubiquitination,
and ¢nally down-modulation.
3.2. Heregulin L1-induced membrane down-modulation and
ubiquitination of p185HER2 requires intact kinase activity
and the presence of ATP
Flow cytometric analysis showed that p185HER2 membrane
expression on MDAMB453 cells was down-modulated after
10 min of treatment of the cells with heregulin L1 (Fig. 2A).
By contrast, cells stimulated with heregulin L1 in the presence
of the kinase inhibitor genistein or in the presence of sodium
azide, an inhibitor of ATP-dependent reactions, showed no
change in membrane expression (Fig. 2B). In the presence
of these two inhibitors, heregulin L1-induced polyubiquitina-
tion was almost completely inhibited (Fig. 3). These data in-
dicate that for the p185HER2 receptor, tyrosine phosphoryla-
tion is a key event in the activation of the ubiquitination
process, as shown previously for other receptors such as
EGFR, PDGF receptor, and TCR [17^19]. Consistent with
Miwazawa’s report on c-kit [20], sodium azide suppressed
the polyubiquitination of p185HER2, indicating the require-
ment for ATP in this phenomenon. Membrane down-modu-
lation of p185HER2 was also blocked by sodium azide, suggest-
ing that the ¢rst event after kinase activation is
ubiquitination, which then leads to endocytosis.
3.3. Heregulin L1-induced p185HER2 degradation involves the
26S proteasome and is necessary for endocytosis
To identify the proteolytic pathway involved in p185HER2
degradation, MDAMB453 cells were treated with LLnL, an
inhibitor of the 26S proteasome. Herbimycin A, a tyrosine
kinase inhibitor, known to induce EGFR and p185HER2 deg-
radation [21], was used as a positive control. In fact, herbi-
mycin A treatment caused the complete disappearance of
p185HER2 and the presence of LLnL prevented herbymicin
A-induced degradation (Fig. 4). When the cells were stimu-
lated with heregulin L1 in the presence of the 26S proteasome
inhibitor, the ligand-induced down-modulation was com-
pletely inhibited (Fig. 5A), and the quantity of polyubiquiti-
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Fig. 1. Western blot analysis of p185HER2 phosphorylation (A), ex-
pression (B), and polyubiquitination (C) in MDAMB453 cells stimu-
lated with heregulin L1 for di¡erent times (min): 0 (lane 1), 1 (lane
2), 5 (lane 3), 15 (lane 4), 30 (lane 5), 60 (lane 6).
Fig. 2. Flow cytometric analysis of p185HER2 membrane expression in: (A) MDAMB453 cells untreated (light line) or treated with heregulin L1
for 10 min (bold line) or pretreated with LLnL overnight followed by heregulin L1 for 10 min (dotted line); (B) MDAMB453 cells untreated
(light line) or treated with genistein (dashed line) or with sodium azide (dotted line) and then stimulated with heregulin L1 for 10 min.
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nated receptor increased (Fig. 5B). These data show that
p185HER2 is degraded by the 26S proteasome pathway, con-
sistent with ¢ndings for other receptors [22].
To determine whether the degradation of p185HER2 occurs
upstream or downstream of its endocytosis, we evaluated the
membrane receptor expression of cells treated with heregulin
L1 in the presence or absence of the 26S proteasome inhibitor
LLnL, by cyto£uorimetry. As shown in Fig. 2A, membrane
down-modulation induced by heregulin L1 was completely
abrogated by LLnL. Thus, endocytosis requires the initiation
of degradation. To date, ubiquitination has been considered
the key event in the induction of endocytosis. However, we
observed an accumulation of polyubiquitinated p185HER2 but
a block of endocytosis following treatment with LLnL, clearly
showing that ubiquitination is not su⁄cient per se to activate
endocytosis and that degradative pathways must also be acti-
vated.
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Fig. 3. Western blot analysis of p185HER2 ubiquitination in
MDAMB453 cells untreated (lanes 1, 2) or treated with sodium
azide (lanes 4, 5) or with genistein (lanes 6, 7) and then stimulated
with heregulin L1 for 0 (lane 1), 10 (lanes 2, 4, 6) or 60 min (lanes
3, 5, 7).
Fig. 4. Western blot analysis of p185HER2 expression in
MDAMB453 cells untreated (lane 1) or treated with herbimycin A
alone (lane 3) or in the presence of LLnL (lane 2).
Fig. 5. Western blot analysis of p185HER2 expression (A) and ubiq-
uitination (B) in MDAMB453 cells untreated (lanes 1^3), or pre-
treated with LLnL overnight (lanes 4, 5) and stimulated with here-
gulin L1 for 10 (lanes 2, 4) or 60 min (lanes 3, 5).
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